Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 20/20 | 0.91 |
| ▸ | ITGB2 | P05107 | 9/20 | 0.91 |
| ▸ | ICAM1 | P05362 | 9/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840803 | 1.00 | ITGAL (0.91) | ITGALITGB2ICAM1 | |
| SCHEMBL3841281 | 0.95 | ITGAL (1.00) | ITGALITGB2ICAM1 | |
| SCHEMBL3841279 | 0.95 | ITGAL (1.00) | ITGALITGB2ICAM1 | |
| SCHEMBL13614165 | 0.89 | ITGAL (0.82) | ITGALITGB2ICAM1 | |
| SCHEMBL5838638 | 0.88 | ITGAL (1.00) | ITGALITGB2ICAM1 | |
| SCHEMBL5838643 | 0.88 | ITGAL (1.00) | ITGALITGB2ICAM1 | |
| SCHEMBL3843132 | 0.88 | ITGAL (0.81) | ITGALITGB2ICAM1 | |
| SCHEMBL3843133 | 0.88 | ITGAL (0.81) | ITGALITGB2ICAM1 | |
| SCHEMBL3842185 | 0.88 | ITGAL (0.95) | ITGALITGB2ICAM1 | |
| SCHEMBL3842186 | 0.88 | ITGAL (0.95) | ITGALITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432700-B1 | SPIRO-HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7078420-B2 | Spiro-hydantoin compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-18 | — | — | US | disclosed |
| US-6977267-B2 | Spiro-hydantoin compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050004153-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | DHAR T G MURALI (US) | 2005-01-06 | — | — | US | disclosed |
| EP-1432700-A4 | SPIRO-HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040248920-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | DHAR T G MURALI (US) | 2004-12-09 | — | — | US | disclosed |
| EP-1432700-A1 | SPIRO-HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | Bristol-Myers Squibb Company (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040009998-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | CEREP SA (FR) | 2004-01-15 | — | — | US | disclosed |
| WO-2003029245-A1 | SPIRO-HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248920-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | ICAM1, VCAM1, SELL | ITGAL 11/4885ITGB2 17/4885ICAM1 1/4885 |
| US-20040009998-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | ICAM1, VCAM1, SELL | ITGAL 11/4885ITGB2 16/4885ICAM1 1/4885 |
| US-20050004153-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | ICAM1, VCAM1, ITGA4 | ITGAL 13/4885ITGB2 12/4885ICAM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.